Translational Research

Our work at the Nanovaccine Institute incorporates advancements in basic research alongside applied clinical practice within a bedside-to-bench-and-back framework. Clinical data inform laboratory research, which in turn, leads back to the bedside of patients for implementation and further scientific discovery and refinement. This framework enables more efficient and cost-effective delivery of promising and robust nanoparticle-based vaccines and therapies to benefit global public health.

The Nanovaccine Institute has expertise in

  • Immunology
  • Nanotechnology
  • Materials Science
  • Microbiology
  • Neuroscience
  • Cancer Biology
  • Vaccine Development, Regulation, and Distribution
  • Gerontology
  • Clinical Science
  • Social Science
  • Animal Health

The Nanovaccine Institute exemplifies translational research through the diverse teams assembled in various ongoing projects that address our health research areas. The Nanovaccine Institute also maintains strong connections with clinicians to determine specific patient needs and wider public health trends.

The typical development timeline for vaccines can take up to 5-10 years, occasionally longer, to assess safety and efficacy. The Nanovaccine Institute’s role in vaccine development is through research and discovery of novel vaccine approaches, spanning preclinical studies through clinical trials. Collaborative partners in vaccine regulation and manufacturing are developing vaccine protocols for commercialization. More information about the vaccine development process and regulation can be found on the US FDA website. Nanovaccine Institute members are developing patents for FDA-approved vaccines and therapeutics that can then be licensed to manufacturers to produce them globally for public benefit.

Projects within the Nanovaccine Institute are at different stages of the research and development process. The most advanced projects are near the end of the pre-clinical stage, and plans are in progress to prepare pre-investigational new drug (IND) applications to the US FDA to determine human safety via Phase I clinical trials.